Kyle W. Sloop

7.3k citations

89 papers · 5.1k indexed · 4 hit papers · h-index 40

Endocrinology, Diabetes and Metabolism top 0.2%
- Diabetes Treatment and Management 47
- Growth Hormone and Insulin-like Growth Factors 7
Endocrine and Autonomic Systems top 1%
- Regulation of Appetite and Obesity 8
Physiology top 2%
- Adipose Tissue and Metabolism 10
Pharmacology top 1%
Cellular and Molecular Neuroscience top 2%
- Neuropeptides and Animal Physiology 15
Surgery
- Pancreatic function and diabetes 30
Molecular Biology
- Receptor Mechanisms and Signaling 26
- Metabolism, Diabetes, and Cancer 9

Co-authors: Francis S. Willard Matthew P. Coghlan Aaron D. Showalter Ricardo J. Samms Simon J. Rhodes Lawrence J. Slieker David A. D’Alessio Tamer Coşkun
Cited by: Endocrinology, Diabetes and Metabolism Endocrine and Autonomic Systems Physiology
Journals: Diabetes (14 papers)Journal of Biological Chemistry (7 papers)Gene (5 papers)
Partner nations: United States Canada Spain

In The Last Decade

Kyle W. Sloop

87 papers receiving 5.0k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2022 Cell Metabolism
2020 JCI Insight
2020 Trends in Endocrinology and Metabolism
2018 Molecular Metabolism

Peers

Countries citing papers authored by Kyle W. Sloop

Since Specialization

Citations

This map shows the geographic impact of Kyle W. Sloop's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kyle W. Sloop with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kyle W. Sloop more than expected).

Fields of papers citing papers by Kyle W. Sloop

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kyle W. Sloop. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kyle W. Sloop. The network helps show where Kyle W. Sloop may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Kyle W. Sloop, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kyle W. Sloop Line = papers co-authored together Kyle W. Sloop links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	α cells use both PC1/3 and PC2 to process proglucagon peptides and control insulin secretion Science Advances ·Elena Yurievna Anisimova,Zhu Jie,Sarah M. Gray,Kimberley El,Victor Poon,Paul A. Grimsrud,Jessica O. Becker,Oleksandr Zanorozhets,Guofang Zhang,Kyle W. Sloop,C. Bruce Verchere,Andrew N. Hoofnagle,David A. D’Alessio,Jonathan E. Campbell	2025	0
2	Characterization of LY3324954 a long-acting glucagon-receptor agonist Molecular Metabolism ·William C. Roell,Tamer Coşkun,Teayoun Kim,Libbey S. O′Farrell,Jennifer A. Martin,Hayu Almar’atus Sholihah,文治堀,Michael Ayers,Daniel J. Drucker,Kyle W. Sloop,Agathe Camus,Jorge Alsina‐Fernandez,Kirk M. Habegger	2024	2
3	Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist Diabetes Therapy ·Xiaosu Ma,Rong Liu,Edward Pratt,Charles Benson,Shobha Bhattachar,Kyle W. Sloop	2024	12
4	Class B1 GPCRs: insights into multireceptor pharmacology for the treatment of metabolic disease American Journal of Physiology-Endocrinology and Metabolism ·Panjamaporn Sangwung,Joseph D. Ho,Modinat Abayomi,刘波,Alejandra Tomás,Ben Jones,Kyle W. Sloop	2024	1
5	GIPR Agonism Enhances TZD-Induced Insulin Sensitivity in Obese IR Mice Diabetes ·Michael Kammen,I. Dragičević,Kyla Collins,Xinxin Yu,Brian A. Droz,N. S. Evseyeva,Jessica L. Friedrich,M R De Felice,Debra L. Konkol,Libbey S. O′Farrell,Hana E. Baker,Tamer Coşkun,Philipp E. Scherer,Christine M. Kusminski,Michael E. Christe,Kyle W. Sloop,Ricardo J. Samms	2023	8
6	Orforglipron ( LY3502970 ), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1a, blinded, placebo‐controlled, randomized, single‐ and multiple‐ascending‐dose study in healthy participants Diabetes Obesity and Metabolism ·Edward Pratt,Xiaosu Ma,Rong Liu,Deborah A. Robins,Axel Haupt,Tamer Coşkun,Kyle W. Sloop,Charles Benson	2023	23
7	Orforglipron ( LY3502970 ), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1b, multicentre, blinded, placebo‐controlled, randomized, multiple‐ascending‐dose study in people with type 2 diabetes Diabetes Obesity and Metabolism ·Edward Pratt,Xiaosu Ma,Rong Liu,Deborah A. Robins,Tamer Coşkun,Kyle W. Sloop,Axel Haupt,Charles Benson	2023	34
8	The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets Nature Metabolism ·Kimberley El,Jonathan D. Douros,Francis S. Willard,Aaron Novikoff,Ashot Sargsyan,Diego Pérez–Tilve,David B. Wainscott,Bin Yang,Victor Poon,Donald Wothe,Yun-a Sung,ez Carlos Francisco Reyes López,Brian Finan,David A. D’Alessio,Kyle W. Sloop,Timo D. Müller,Jonathan E. Campbell	2023	74
9	14-3-3-zeta mediates GLP-1 receptor agonist action to alter α cell proglucagon processing Science Advances ·Marlena M. Holter,Limnanthes Serafini,Angela M. Rojas-Arevalo,Mridusmita Saikia,VA Kalsin,A W Suliman,Elizabeth T. Anderson,Qin Fu,Sheng Zhang,Kyle W. Sloop,Bethany P. Cummings	2022	10
10	Discordance between GLP-1R gene and protein expression in mouse pancreatic islet cells Journal of Biological Chemistry ·Sarah M. Gray,Yurong Xin,Liz Ross,M. Bogdanić,Megan E. Capozzi,Kimberley El,Berit Svendsen,Peter Ravn,Kyle W. Sloop,Jenny Tong,Jesper Gromada,Jonathan E. Campbell,David A. D’Alessio	2020	29
11	Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonistbreakdown → JCI Insight ·Francis S. Willard,Jonathan D. Douros,M Gabe,Aaron D. Showalter,David B. Wainscott,Todd M. Suter,Megan E. Capozzi,Wijnand J. C. van der Velden,Cynthia Stutsman,Guemalli R. Cardona,Shweta Urva,Paul J. Emmerson,Jens J. Holst,David A. D’Alessio,Matthew P. Coghlan,Mette M. Rosenkilde,Jonathan E. Campbell,Kyle W. Sloop	2020	314
12	LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of conceptbreakdown → Molecular Metabolism ·Tamer Coşkun,Kyle W. Sloop,Corina Loghin,Jorge Alsina‐Fernandez,Shweta Urva,Krister Bokvist,Xuewei Cui,Daniel A. Briere,Over Cabrera,William C. Roell,Ritin Patel,Julie S. Moyers,Charles Benson,Ruth E. Gimeno,David A. D’Alessio,Axel Haupt	2018	603
13	Glucagon-Like Peptide-1 Receptor Ligand Interactions: Structural Cross Talk between Ligands and the Extracellular Domain PLoS ONE ·Graham M. West,Francis S. Willard,Kyle W. Sloop,Aaron D. Showalter,Bruce D. Pascal,Patrick R. Griffin	2014	11
14	The Furan Fatty Acid Metabolite CMPF Is Elevated in Diabetes and Induces β Cell Dysfunction Cell Metabolism ·Kacey J. Prentice,Maria El-Abd,Emma M. Allister,Ying Liu,Lucy S. Jun,Kyle W. Sloop,Alexandre B. Hardy,Li Wei,Weiping Jia,I. George Fantus,Douglas H. Sweet,Gary Sweeney,Ravi Retnakaran,Feihan F. Dai,Michael B. Wheeler	2014	132
15	Small Molecule Allosteric Modulation of the Glucagon-Like Peptide-1 Receptor Enhances the Insulinotropic Effect of Oxyntomodulin Molecular Pharmacology ·Francis S. Willard,Denise Wootten,Aaron D. Showalter,Emilia E. Savage,James Ficorilli,Thomas B. Farb,Krister Bokvist,Jorge Alsina‐Fernandez,Sebastian G. B. Furness,Arthur Christopoulos,Patrick M. Sexton,Kyle W. Sloop	2012	44
16	Suppression of choroid plexus transthyretin levels by antisense oligonucleotide treatment Amyloid ·Merrill D. Benson,Richard Smith,Gene Hung,Barbara Kluve‐Beckerman,Aaron D. Showalter,Kyle W. Sloop,Brett P. Monia	2010	34
17	Conserved amino acid sequences confer nuclear localization upon the Prophet of Pit-1 pituitary transcription factor protein Gene ·Erico Wildan Kurniawan,Chad S. Hunter,Aaron D. Showalter,Timothy P. L. Smith,Riffat Naz Akhtar,Kyle W. Sloop,Joseph P. Bidwell,Simon J. Rhodes	2004	13
18	Role of the LIM domains in DNA recognition by the Lhx3 neuroendocrine transcription factor Gene ·Alice Valdez,Jeffrey R. Price,Gretchen E. Parker,Juan Diego Cagua Gutierrez,Kyle W. Sloop,Simon J. Rhodes	2001	37
19	Identification of porcine Lhx3 and SF1 as candidate genes for QTL affecting growth and reproduction traits in swine Animal Genetics ·Timothy P. L. Smith,Aaron D. Showalter,Kyle W. Sloop,G. A. Rohrer,Scott C. Fahrenkrug,Flávia Heiderich Dall'Orto,Simon J. Rhodes	2001	13
20	Analysis of the human LHX3 neuroendocrine transcription factor gene and mapping to the subtelomeric region of chromosome 9 Gene ·Kyle W. Sloop,Aaron D. Showalter,Paula Turunen,Mark J. Pettenati,Simon J. Rhodes	2000	30

About Kyle W. Sloop

Kyle W. Sloop is a scholar working on Endocrinology, Diabetes and Metabolism, Endocrine and Autonomic Systems and Cellular and Molecular Neuroscience, having authored 89 papers that have together received 5.1k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (47 papers), Pancreatic function and diabetes (30 papers), Receptor Mechanisms and Signaling (26 papers), Neuropeptides and Animal Physiology (15 papers), Adipose Tissue and Metabolism (10 papers), Metabolism, Diabetes, and Cancer (9 papers), Regulation of Appetite and Obesity (8 papers) and Growth Hormone and Insulin-like Growth Factors (7 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (2.7k citations), Endocrine and Autonomic Systems (689 citations) and Physiology (1.2k citations). Kyle W. Sloop has collaborated with scholars based in United States, Canada and Spain. Frequent co-authors include Francis S. Willard, Matthew P. Coghlan, Aaron D. Showalter, Ricardo J. Samms, Simon J. Rhodes, Lawrence J. Slieker, David A. D’Alessio, Tamer Coşkun, Daniel A. Briere and Shweta Urva. Their work appears in journals such as Diabetes, Journal of Biological Chemistry, Gene, Endocrinology and Molecular Metabolism.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact